Efmoroctocog Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Efmoroctocog Alfa: From Hemophilia A to Pseudo-von Willebrand Disease
One-Sentence Summary
Efmoroctocog alfa is a long-acting recombinant Factor VIII (Factor VIII-Fc fusion protein), originally used for Factor VIII replacement therapy in hemophilia A. The TxGNN model predicts potential benefit for Pseudo-von Willebrand Disease, but currently there is no clinical trial or literature evidence supporting this direction, and the model’s own mechanism description notes this association as “indirect and weak.”
Quick Overview
| Item | Content |
|---|---|
| Original indication | Hemophilia A (based on candidate indication mechanism description; official approved indication text currently unavailable) |
| Predicted new indication | Pseudo-von Willebrand Disease |
| TxGNN prediction score | 99.997% |
| Evidence level | L5 (model prediction only, no clinical trial or literature) |
| Market status | Not marketed |
| Number of approved drug licenses | 0 |
| Recommended decision | Hold |
Is This Prediction Reasonable?
Complete mechanism of action data for Efmoroctocog alfa has not yet been obtained (MOA is a Data Gap). Based on mechanism descriptions for other candidate indications, Efmoroctocog alfa is a long-acting recombinant Factor VIII-Fc fusion protein (rFVIII-Fc), originally intended to supplement the insufficient Factor VIII in patients with hemophilia A.
For the top-ranked Pseudo-von Willebrand Disease (platelet-type VWD), its pathological root cause is abnormality in the platelet GPIb receptor leading to excessive binding and clearance of von Willebrand factor, not a deficiency of Factor VIII (FVIII) itself. Although FVIII and VWF form complexes in plasma, the fundamental defect in this disease lies in the platelet receptor rather than FVIII concentration, making it difficult for FVIII supplementation to correct the core pathophysiological problem. The mechanism description provided by the model also explicitly states that this association is “indirect and weak, with no trial or literature support.”
It is worth noting that among the 10 candidates in this prediction list, the one with the strongest mechanism association is actually rank 9 “hemophilia A with vascular abnormality”—essentially a subtype of hemophilia A combined with vascular abnormality, directly overlapping with the original indication—but its TxGNN score (99.78%) and rank (rank 900) are both lower than the top-ranked Pseudo-von Willebrand Disease (rank 54). This indicates that the candidate with the highest score is not necessarily the most mechanistically reasonable candidate, and should be considered together during evaluation.
Clinical Trial Evidence
Currently, there are no related clinical trial registrations.
Literature Evidence
Currently, there is no related literature data.
Drug Marketing Information
This drug is currently Not marketed in the jurisdiction of this database (number of approved drug licenses: 0), with no approved indication text available for excerpt.
Safety Considerations
Please refer to the product information leaflet (SmPC) for safety information.
Additionally, it should be noted that this assessment has a Blocking-level data gap (EMA package insert warnings/contraindications have not yet been obtained), and cannot enter the safety initial assessment (S1) stage until this gap is filled.
Conclusion and Recommendations for Follow-up
Decision: Hold
Rationale:
- The only evidence supporting this prediction is the TxGNN model score, with no clinical trial or literature support;
- The model’s own mechanism description has characterized this association as “indirect and weak”;
- EMA package insert warnings/contraindications data is a Blocking-level data gap, and the conditions are not yet met to proceed to the next stage of safety assessment.
To proceed, the following gaps need to be filled:
- TFDA product information leaflet warnings and contraindications data (DG001, Blocking)
- Complete mechanism of action (MOA) data for Efmoroctocog alfa (DG002, High)
- Upon reassessment, it is recommended to prioritize reviewing candidates with higher mechanism overlap—such as rank 9 “hemophilia A with vascular abnormality”—rather than the currently highest-scoring but mechanistically weak rank 1 candidate
- Supplement literature search on whether alternative therapeutic mechanisms targeting platelet function exist for Pseudo-von Willebrand Disease
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.